{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:28:11Z","timestamp":1790519291446,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.canlet.2019.12.016","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T13:42:10Z","timestamp":1576158130000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma"],"prefix":"10.1016","volume":"472","author":[{"given":"B\u00e9atrice","family":"Vanbervliet-Defrance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Daunizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahan","family":"Kepenekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Estornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ziverec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Djemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantu\u00e9joul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Micheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-3747","authenticated-orcid":false,"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufic","family":"Renno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-8319","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Fonteneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar\u00e8ne","family":"Mahtouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.12.016_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.coi.2012.11.001","article-title":"TLR3 immunity to infection in mice and humans","volume":"25","author":"Zhang","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib2","article-title":"Trial Watch: Toll-like receptor agonists for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.12.016_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrc2541","article-title":"Toll-like receptors and cancer","volume":"9","author":"Rakoff-Nahoum","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.12.016_bib4","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","article-title":"TLR3 can directly trigger apoptosis in human cancer cells","volume":"176","author":"Salaun","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib5","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-07-0603","article-title":"Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma","volume":"13","author":"Morikawa","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib6","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1111\/j.1365-2567.2008.03041.x","article-title":"Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas","volume":"128","author":"Rydberg","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2019.12.016_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-9378-7-36","article-title":"Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic","volume":"7","author":"Verillaud","year":"2012","journal-title":"Infect. Agents Cancer"},{"key":"10.1016\/j.canlet.2019.12.016_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/carcin\/bgn149","article-title":"Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism","volume":"29","author":"Paone","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2019.12.016_bib9","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.4049\/jimmunol.0803113","article-title":"TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production","volume":"182","author":"Chiron","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/cdd.2012.22","article-title":"dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8","volume":"19","author":"Estornes","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2019.12.016_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41419-018-0850-0","article-title":"Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis","volume":"9","author":"Alkurdi","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2019.12.016_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molcel.2011.06.011","article-title":"cIAPs block Ripoptosome formation, a RIP1\/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms","volume":"43","author":"Feoktistova","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2019.12.016_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.humpath.2016.04.015","article-title":"Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array","volume":"55","author":"Chirac","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2019.12.016_bib14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2019.12.016_bib15","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.12.016_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"French Cooperative Thoracic I. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.12.016_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2019.12.016_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2019.12.016_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2019.12.016_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4049\/jimmunol.1202173","article-title":"Cleaved\/associated TLR3 represents the primary form of the signaling receptor","volume":"190","author":"Toscano","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib21","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3389\/fimmu.2017.01897","article-title":"Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy","volume":"8","author":"Matsumoto","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.12.016_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature04734","article-title":"Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses","volume":"441","author":"Kato","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.12.016_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","article-title":"Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2019.12.016_bib25","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/0008-5472.CAN-08-0673","article-title":"Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells","volume":"68","author":"Abedini","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib26","first-page":"4255","article-title":"Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells","volume":"9","author":"Song","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B","article-title":"Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas\/CD95-mediated apoptosis by down-regulating FLIP-L expression","volume":"88","author":"Kinoshita","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.12.016_bib28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","article-title":"IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis","volume":"131","author":"Varfolomeev","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.12.016_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.12.016_bib30","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1158\/0008-5472.CAN-11-4134","article-title":"The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells","volume":"72","author":"Shatz","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jnci\/89.11.783","article-title":"Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity","volume":"89","author":"Micheau","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2019.12.016_bib32","first-page":"847","article-title":"Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo","volume":"60","author":"Nagane","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ijc.21283","article-title":"Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma","volume":"118","author":"Kondo","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2019.12.016_bib34","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-05-0262","article-title":"Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP","volume":"4","author":"Galligan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.12.016_bib35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/cdd.2009.190","article-title":"Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells","volume":"17","author":"Weber","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2019.12.016_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nri.2017.9","article-title":"Dying cells actively regulate adaptive immune responses","volume":"17","author":"Yatim","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.12.016_bib37","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10495-006-9527-8","article-title":"Clearance of apoptotic and necrotic cells and its immunological consequences","volume":"11","author":"Krysko","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2019.12.016_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aad0395","article-title":"RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells","volume":"350","author":"Yatim","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2019.12.016_bib39","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.12.016_bib40","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1074\/jbc.274.12.7987","article-title":"Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs","volume":"274","author":"Micheau","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2019.12.016_bib41","first-page":"203","article-title":"Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas\/FasL (CD95\/APO1) signaling pathway","volume":"6","author":"Ferreira","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.016_bib42","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1535-7163.MCT-16-0454","article-title":"The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects","volume":"16","author":"Ding","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.12.016_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13402-018-0403-7","article-title":"Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2","volume":"42","author":"Mikulandra","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2019.12.016_bib44","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1038\/ncomms7280","article-title":"Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo","volume":"6","author":"Matsumoto","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2019.12.016_bib45","doi-asserted-by":"crossref","first-page":"283649","DOI":"10.1155\/2013\/283649","article-title":"Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100","volume":"2013","author":"Naumann","year":"2013","journal-title":"Clin. Dev. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:45:27Z","timestamp":1759592727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519306226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":45,"alternative-id":["S0304383519306226"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.12.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}